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Abstract 
Normal tension glaucoma (NTG) remains a therapeutic challenge for the ophthalmologist since 
there are no effective therapies as the main therapeutic target, i.e., the intraocular pressure 
(IOP) increase, is missed. We report on the effectiveness of two neuroprotective molecules 
(ultrapure citicoline plus homotaurine), in combination with a topical hypotensive approach, in 
the management of NTG in a long-term follow-up (30 months). A 38-year-old Caucasian 
woman with no significant medical history and a diagnosis of NTG, after an extensive 30-month 
treatment with oral dietary supplement containing ultrapure citicoline 500 mg, homotaurine 
50 mg and vitamin E once per day and topical glaucoma medication (brimonidine + brinzola-
mide drops twice per day), presented a significantly improved automated 24-2 visual field with 
a controlled tonometric measurement associated with a stabilization of retinal fiber layer and 
ganglion cells at OCT examination with patient satisfaction. This finding suggests that ultrapure 
citicoline together with homotaurine and vitamin E, through a synergistic neuroprotective ef-
fect, could be a promising approach in the management of NTG. 
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Normal tension glaucoma (NTG) is a form of open-angle glaucoma (OAG), which presents 
with typical alterations of the optic nerve head and functional visual field loss but normal in-
traocular pressure (IOP) findings [1]. 
The incidence is 30–40% of all patients diagnosed with a glaucomatous visual field defect; 
the etiology has not been well defined yet, however, it seems to be multifactorial and it is often 
associated with vascular dysregulation, nocturnal hypotension and abnormal optic nerve per-
fusion [2].  
The treatment of NTG is somehow discussed since it misses the major therapeutic target, 
i.e., the elevated IOP. The Collaborative Normal Tension Glaucoma Study showed that patients 
in whom 30% or more reduction of IOP is achieved have a slowed disease progression [3]. 
Topical brimonidine-treated patients seem to have less likely visual field progression com-
pared to timolol-treated patients [4]; however, the current gold standard in medical therapy 
for NTG is the use of topical prostaglandin analogues [5, 6]. In recent years, attention has 
shifted towards systemic neuroprotection in OAG with specific nutritional supplementations; 
however, their use in NTG is still discussed [7, 8].  
Ultrapure citicoline or cytidine-5-diphosphochilone (CDP-choline, Cognizin®) is an en-
dogenous molecule crucial in the processes of formation and restoration of the neuron cells 
interacting with the synthesis of phospholipids of membrane cells [9]; moreover, this mole-
cule is important for the formation of acetylcholine, which is an essential neurotransmitter for 
nerve impulses in brain tissue. Its neuroprotective action has been proven in many neuro-
degenerative disorders such as Alzheimer disease, Parkinson disease and glaucoma [10]. Ul-
trapure citicoline has also shown to improve attentional performances in healthy adult 
women and to improve psychomotor speed in adolescent males [11, 12]. 
Homotaurine (3-aminopeopanesulfonate) is an amino acid derivative that can help to im-
prove the propagation of nervous impulse in the central nervous system. A recent study 
demonstrated that the co-treatment with citicoline and homotaurine has a positive and syn-
ergistic effect on cell survival in retinal cultures simulating retinal neurodegeneration in ex-
perimental conditions. [13]. 
Vitamin E (alpha-tocopherol) is an antioxidant molecule that promotes cellular protec-
tion [14]. 
We report a case of a young female treated with ultrapure citicoline, homotaurine and 
vitamin E in the management of NTG. 
Case Report 
A 38-year-old woman was referred to our service for a general ophthalmological visit 
(baseline visit). No significant general diseases were encountered. She referred frequent mi-
graine episodes. No family history for ocular diseases was registered. Best corrected visual 
acuity was 20/20 with refraction of –0.75 and –1.75 (170) in the right eye (RE) and 20/20 
with –2.00 (160) in the left eye (LE). The IOP was 14 and 12 mm Hg for the RE and LE, respec-
tively. The anterior segment biomicroscopy was unremarkable bilaterally. The iridocorneal 
angle was opened within normality with all angle’s structures well visible. During the ophthal-
moscopy, an abnormal excavation of the optic nerve head was found bilaterally. A Humphrey 
visual field (HVF, Carl Zeiss Meditech, Dublin, CA, USA) 24-2 SITA standard testing and a reti-
nal nerve fiber layer (RNFL), ganglion cells (GC) and corneal pachymetry examination at the 
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OCT (Cirrus 4000 HD-OCT, Carl Zeiss Meditec, Dublin, CA, USA) were performed (Fig. 1, Fig. 2, 
Fig. 3).  
In particular, the mean deviation (MD) in RE was –11.70 and in LE –5.45. False negative 
errors were 26% in RE and 0% in LE. The mean RNFL was 76 μm in both eyes, while GC was 
76 μm in RE and 66 μm in LE. Cup-to-disc ratio (C/D) was 0.83 in both eyes. The corneal 
pachymetry resulted in 512 μm and 516 μm for RE and LE, respectively. 
We requested orbital and encephalic magnetic resonance imaging (MRI). Topical therapy 
with brimatoprost drops 0.1 mg/mL once per day was started. 
At the 1-month follow-up, the IOP was 11 mm Hg in RE and 9 mm Hg in LE. However, due 
to conjunctival redness and discomfort reported by the patient, we modified topical therapy 
prescribing brimonidine + brinzolamide drops twice per day and we started oral supplemen-
tation with ultrapure citicoline 500 mg, homotaurine 50 mg and vitamin E (Neuprozin tablets, 
FB Vision, 63100 Ascoli Piceno, Italy) once per day for 3 months followed by a break of  
1 month. She was asked to continue therapy until further notice. 
MRI, performed within 2 weeks, showed no significant alterations.  
At the 3-month follow-up, HVF improved (MD RE from –11.70 to –7.87, LE from –5.45 to 
–3.47), false negative errors were 8% in RE and 10% in LE. RNFL and GC were stable. The IOP 
was 11 mm Hg in RE and 10 mm Hg in LE. We requested a 24-h Holter pressure monitoring. 
The 24-h Holter pressure monitoring showed a day mean systolic pressure of 114 mm Hg 
and a diastolic pressure of 73 mm Hg; in the night, the mean systolic pressure was 107 mm Hg 
and the mean diastolic pressure was 56 mm Hg. The patient was diagnosed with a mild lower 
blood pressure. 
At the 8-month follow-up, the IOP was 11 mm Hg bilaterally. Topical drops and oral ther-
apy were continued. At the 10-month follow-up, the IOP was 10 mm Hg.  
At the 12-month follow-up, HVF was improved (MD RE –6.71, LE –1.20; false negative 
errors were 7% in RE and 0% in LE) and RNFL and GC at OCT were stable. The IOP was 11 
mm Hg bilaterally. She continued with the prescribed therapy. 
The patient did not attend regular checks for 1 year for personal reasons.  
She came back to our clinic for control after 24 months. She reported to have continued 
the same therapy (oral and topical). The IOP was 11 mm Hg bilaterally. HVF improved, partic-
ularly on the right side (MD RE –1.92, LE –2.15). False negative errors were 6% in RE and 1% 
in LE, RNFL and GC remained stable. The C/D ratio was 0.84 bilaterally. 
At the 30-month follow-up visit, the IOP was 11 mm Hg in RE and 10 mm Hg in LE. HVF 
presented further improvements (MD RE –0.92, LE –0.70). False negative errors were 1% in 
RE and 0% in LE; RNFL and GC remained stable. 
The follow-up data are shown in Figures 4 and 5. 
Discussion / Conclusion 
In this case report, we speculate about the utility of using nutritional supplements based 
on ultrapure citicoline associated with homotaurine and vitamin E in the management of NTG. 
Neuroenhancement of neural conduction is a relatively new field in glaucoma manage-
ment. Synergistic multitarget approach with a combination of neuroprotective compounds 
may be a promising strategy to slow down the progression of glaucoma. NTG remains a ther-
apeutic challenge for the ophthalmologist since there are no effective therapies as the main 
therapeutic target, the IOP increase, is missed. 
 
Case Rep Ophthalmol 2020;11:222–228 
DOI: 10.1159/000507881 © 2020 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/cop 






A recent study demonstrated that the combination of citicoline and homotaurine has a 
synergistic neuroprotective effect on experimental neuroretinal degeneration reducing apop-
tosis of primary retinal cells thus being a potential new strategy for the prevention and treat-
ment of neurodegenerative diseases [10]. 
Moreover, the combination with vitamin E, which is an antioxidant molecule, can improve 
the neuroenhancement promoting cellular protection [14]. 
In our report, we describe an improvement in the visual field defect in a young female 
affected by NTG treated with ultrapure citicoline, homotaurine and vitamin E supplementa-
tion in a 30-month follow-up. We did not have any change of the OCT parameters during the 
follow-up and this could be considered a positive effect for the stabilization of RNFL and GC 
during the treatment.  
This report has some limitations to be considered. Firstly, HVF is a subjective psycho-
physical test that could be influenced by many factors (such as a patient who is tired or wor-
ried, minor differences in room illumination, etc.). An electrophysiological examination could 
be more reliable giving more objective data. We also cannot exclude a learning effect in HVF 
performance in a young patient especially for the first exam in the RE at baseline. Finally, the 
concomitant use of brimonidine topical drops could have added a neuroprotective effect that 
could have caused a synergistic effect. 
In conclusion, our finding suggests that the use of ultrapure citicoline together with ho-
motaurine and vitamin E through a synergistic neuroprotective effect could be a promising 
approach in the management of NTG. Controlled clinical trials will be needed in the future to 
confirm these data. 
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Fig. 4. Progression of the VF during the follow-up for both eyes. MD, mean deviation; PSD, pattern standard 




Fig. 5. Guided progression analysis (GPA) during the 2-year follow-up for both eyes. RNFL and C/D ratio 
remained stable. 
 
